© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
July 13, 2020
Jae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
May 18, 2020
Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.
May 01, 2020
Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.
February 19, 2015
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.